Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Decreases By 53.7%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant decline in short interest in April. As of April 30th, there was short interest totaling 37,414 shares, a decline of 53.7% from the April 15th total of 80,782 shares. Based on an average daily trading volume, of 137,830 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.5% of the company’s stock are sold short.

Catheter Precision Stock Down 1.4%

VTAK traded down $0.01 during trading on Friday, reaching $0.76. The company had a trading volume of 33,645 shares, compared to its average volume of 783,306. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.10 and a quick ratio of 0.08. Catheter Precision has a 12 month low of $0.76 and a 12 month high of $15.68. The business’s fifty day moving average price is $1.09 and its 200 day moving average price is $1.69. The company has a market cap of $2.05 million, a P/E ratio of -0.04 and a beta of -1.04.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the Securities and Exchange Commission (SEC). 20.34% of the stock is owned by institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.